{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:24:17Z","timestamp":1790267057185,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T00:00:00Z","timestamp":1642377600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013327","name":"H Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.clinthera.2022.01.006","type":"journal-article","created":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T03:09:40Z","timestamp":1644030580000},"page":"389-402","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Impact of Baseline Characteristics on the Efficacy and Safety of Eptinezumab in Patients With Migraine: Subgroup Analyses of PROMISE-1 and PROMISE-2"],"prefix":"10.1016","volume":"44","author":[{"given":"Vincent","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Jim","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Janelidze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gvantsa","family":"Giorgadze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Hirman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Cady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lahar","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn C.","family":"Buse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2022.01.006_bib0001","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/head.13281","article-title":"The prevalence and impact of migraine and severe headache in the United States: figures and trends from government health studies","volume":"58","author":"Burch","year":"2018","journal-title":"Headache"},{"key":"10.1016\/j.clinthera.2022.01.006_bib0002","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s10194-020-1084-y","article-title":"Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the Migraine in America Symptoms and Treatment (MAST) study","volume":"21","author":"Buse","year":"2020","journal-title":"J Headache Pain"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2022.01.006_bib0003","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/head.12505_2","article-title":"Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention","volume":"55","author":"Lipton","year":"2015","journal-title":"Headache"},{"key":"10.1016\/j.clinthera.2022.01.006_bib0004","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s10194-019-1010-3","article-title":"Optimising migraine treatment: from drug-drug interactions to personalized medicine","volume":"20","author":"Pomes","year":"2019","journal-title":"J Headache Pain"},{"key":"10.1016\/j.clinthera.2022.01.006_bib0005","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1212\/WNL.0000000000003919","article-title":"Body composition status and the risk of migraine: a meta-analysis","volume":"88","author":"Gelaye","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2022.01.006_bib0006","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s10194-020-01163-w","article-title":"Migraine, obesity and body fat distribution\u2014a population-based study","volume":"21","author":"Kristoffersen","year":"2020","journal-title":"J Headache Pain"},{"key":"10.1016\/j.clinthera.2022.01.006_bib0007","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1526-4610.2005.05064.x","article-title":"Disability associated with headaches occurring inside and outside the menstrual period in those with migraine: a general practice study","volume":"45","author":"Dowson","year":"2005","journal-title":"Headache"},{"key":"10.1016\/j.clinthera.2022.01.006_bib0008","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s13311-018-0622-7","article-title":"The biology of monoclonal antibodies: focus on calcitonin gene-related peptide for prophylactic migraine therapy","volume":"15","author":"Raffaelli","year":"2018","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.clinthera.2022.01.006_bib0009","doi-asserted-by":"crossref","first-page":"e00567","DOI":"10.1002\/prp2.567","article-title":"Population pharmacokinetic and exposure-response analysis of eptinezumab in the treatment of episodic and chronic migraine","volume":"8","author":"Baker","year":"2020","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.clinthera.2022.01.006_bib0010","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.88.16_supplement.P2.155","article-title":"Rational design of a monoclonal antibody (mAB) inhibiting calcitonin gene-related peptide (CGRP), ALD403, intended for the prevention of migraine (p2.155)","volume":"88","author":"Baker","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2022.01.006_bib0011","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1124\/jpet.119.264671","article-title":"Pharmacologic characterization of ALD403, a potent neutralizing humanized monoclonal antibody against the calcitonin gene-related peptide","volume":"374","author":"Garcia-Martinez","year":"2020","journal-title":"JPET"},{"key":"10.1016\/j.clinthera.2022.01.006_bib0012","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/0333102420905132","article-title":"Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1)","volume":"40","author":"Ashina","year":"2020","journal-title":"Cephalalgia"},{"key":"10.1016\/j.clinthera.2022.01.006_bib0013","doi-asserted-by":"crossref","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","article-title":"Efficacy and safety of eptinezumab in patients with chronic migraine. PROMISE-2","volume":"94","author":"Lipton","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2022.01.006_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"The International Classification of Headache Disorders, 3rd edition","volume":"38","year":"2018","journal-title":"Cephalalgia"},{"key":"10.1016\/j.clinthera.2022.01.006_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/head.13456","article-title":"The American Headache Society position statement on integrating new migraine treatments into clinical practice","volume":"59","year":"2019","journal-title":"Headache"},{"key":"10.1016\/j.clinthera.2022.01.006_bib0016","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1177\/0333102419828967","article-title":"Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: fourth edition","volume":"39","author":"Diener","year":"2019","journal-title":"Cephalalgia"},{"key":"10.1016\/j.clinthera.2022.01.006_bib0017","first-page":"1334","article-title":"Burden of illness among people with migraine and \u2265 4 monthly headache days while using acute and\/or preventive prescription medications for migraine","volume":"26","author":"Buse","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.clinthera.2022.01.006_bib0018","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1177\/0333102414552532","article-title":"The impact of chronic migraine: the Chronic Migraine Epidemiology and Outcomes (CaMEO) study methods and baseline results","volume":"35","author":"Adams","year":"2015","journal-title":"Cephalalgia"},{"key":"10.1016\/j.clinthera.2022.01.006_bib0019","doi-asserted-by":"crossref","first-page":"e00217","DOI":"10.1002\/edm2.217","article-title":"Tolerability of eptinezumab in overweight, obese or type 1 diabetes patients","volume":"4","author":"Baker","year":"2021","journal-title":"Endocrinol Diabetes Metab"},{"key":"10.1016\/j.clinthera.2022.01.006_bib0020","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/0196-9781(91)90147-H","article-title":"Calcitonin gene-related peptide in human obesity","volume":"12","author":"Zelissen","year":"1991","journal-title":"Peptides"},{"key":"10.1016\/j.clinthera.2022.01.006_bib0021","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2165\/11318100-000000000-00000","article-title":"Effect of obesity on the pharmacokinetics of drugs in humans","volume":"49","author":"Hanley","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2022.01.006_bib0022","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/17425255.2018.1440287","article-title":"Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters","volume":"14","author":"Smit","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822000108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822000108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:56:18Z","timestamp":1758963378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291822000108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0149291822000108"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.01.006","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Baseline Characteristics on the Efficacy and Safety of Eptinezumab in Patients With Migraine: Subgroup Analyses of PROMISE-1 and PROMISE-2","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}